Immunotherapy of mouse renal cell carcinoma with tumor lysate-pulsed dendritic cells

薛松,孙颖浩,高建平,葛京平,许传亮,朱学军,范振芳

DOI: https://doi.org/10.3969/j.issn.1008-8199.2010.05.008

2010-01-01

Abstract:Objective Dendritic cells(DC)-based tumor vaccines are the hot-point of immunotherapy in recent years.This study is to observe the therapeutic effect on mouse renal cell carcinoma with tumor lysate pulsed DC.Methods Tumor antigens were prepared from repeated freeze-thaw tumor lysate,Lowry method was used to determine protein concentration.Recombinant mouse GM-CSF and IL-4 were used to expand mouse bone marrow derived DC.Pulsed tumor lysate in vitro was used for preparation of DC vaccine.DC vaccines were cultured with lymphocytes to induce cytolytic T lymphocyte(CTL) in vitro.LDH release methods were used to determine anti-tumor activity of the CTL.Mice were inoculated subcutaneously with Ranca cells,and after 72h,DC vaccines were inoculated subcutaneously once a week for 3 times.Four weeks later the tumors were seized and weighed.Results The mouse renal cell carcinoma lysate pulsed DC had the typical morphological features and immunophenotypic characteristics of mature DC.DC vaccine could effectively induce Ranca-specific CTL in vitro.The tumor volume of mice injected with DC vaccine was significantly reduced compared with NS control group and LAK cell therapy group.The tumor weight of DC vaccine treated mice decreased significantly compared with NS control group(P<0.01) and LAK cell therapy group(P<0.05).Conclusion The tumor lysate pulsed DC vaccine has obvious therapeutic effect for mouse renal cell carcinoma.This study provides an experimental basis for DC vaccine immunotherapy of renal cell carcinoma.